Anavex Life Sciences Analyst Ratings
Anavex Life Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/28/2023 | 750.39% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 08/08/2023 | 750.39% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 07/20/2023 | — | HC Wainwright & Co. | Reiterates | Buy → Buy | |
| 06/29/2023 | 750.39% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 05/02/2023 | 750.39% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/31/2023 | 750.39% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 02/09/2023 | 340.94% | BTIG | $35 → $28 | Maintains | Buy |
| 02/09/2023 | 687.4% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/06/2023 | 687.4% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/03/2023 | 687.4% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 12/06/2022 | 73.23% | Cantor Fitzgerald | $16 → $11 | Downgrades | Overweight → Neutral |
| 06/23/2022 | 529.92% | Berenberg | → $40 | Initiates Coverage On | → Buy |
| 02/02/2022 | 561.42% | HC Wainwright & Co. | $39 → $42 | Maintains | Buy |
| 09/23/2021 | 451.18% | BTIG | → $35 | Initiates Coverage On | → Buy |
| 06/28/2021 | 514.17% | HC Wainwright & Co. | $25 → $39 | Maintains | Buy |
| 06/15/2021 | 293.7% | HC Wainwright & Co. | $17 → $25 | Maintains | Buy |
| 02/23/2021 | 293.7% | Cantor Fitzgerald | $10 → $25 | Reiterates | → Overweight |
| 12/16/2020 | 167.72% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
| 10/21/2020 | 120.47% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
| 09/28/2020 | 88.98% | Ladenburg Thalmann | → $12 | Initiates Coverage On | → Buy |
| 03/16/2020 | 88.98% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 07/24/2019 | 151.97% | Dawson James | → $16 | Initiates Coverage On | → Buy |
| 06/18/2019 | 57.48% | Janney Montgomery Scott | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/28/2023 | 750.39% | HC Wainwright & Co. | → 54 美元 | 重申 | 購買 → 購買 |
| 08/08/2023 | 750.39% | HC Wainwright & Co. | → 54 美元 | 重申 | 購買 → 購買 |
| 07/20/2023 | — | HC Wainwright & Co. | 重申 | 購買 → 購買 | |
| 06/29/2023 | 750.39% | HC Wainwright & Co. | → 54 美元 | 重申 | 購買 → 購買 |
| 05/02/2023 | 750.39% | HC Wainwright & Co. | → 54 美元 | 重申 | → 購買 |
| 03/31/2023 | 750.39% | HC Wainwright & Co. | 50 美元 → 54 美元 | 維護 | 買 |
| 02/09/2023 | 340.94% | BTIG | 35 美元 → 28 美元 | 維護 | 買 |
| 02/09/2023 | 687.4% | HC Wainwright & Co. | → 50 美元 | 重申 | → 購買 |
| 02/06/2023 | 687.4% | HC Wainwright & Co. | → 50 美元 | 重申 | → 購買 |
| 01/03/2023 | 687.4% | HC Wainwright & Co. | 42 美元 → 50 美元 | 維護 | 買 |
| 12/06/2022 | 73.23% | 坎託·菲茨傑拉德 | 16 美元 → 11 美元 | 降級 | 超重 → 中性 |
| 06/23/2022 | 529.92% | 貝倫貝格 | → 40 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 02/02/2022 | 561.42% | HC Wainwright & Co. | 39 美元 → 42 美元 | 維護 | 買 |
| 2021 年 9 月 23 日 | 451.18% | BTIG | → 35 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 6 月 28 日 | 514.17% | HC Wainwright & Co. | 25 美元 → 39 美元 | 維護 | 買 |
| 06/15/2021 | 293.7% | HC Wainwright & Co. | 17 美元 → 25 美元 | 維護 | 買 |
| 2021 年 2 月 23 日 | 293.7% | 坎託·菲茨傑拉德 | 10 美元 → 25 美元 | 重申 | → 超重 |
| 2020 年 12 月 16 日 | 167.72% | HC Wainwright & Co. | 14 美元 → 17 美元 | 維護 | 買 |
| 10/21/2020 | 120.47% | HC Wainwright & Co. | 12 美元 → 14 美元 | 維護 | 買 |
| 09/28/2020 | 88.98% | 拉登堡塔爾曼 | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/16/2020 | 88.98% | HC Wainwright & Co. | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 07/24/2019 | 151.97% | 道森·詹姆斯 | → 16 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/18/2019 | 57.48% | 詹尼蒙哥馬利斯科特 | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Anavex Life Sciences (AVXL)?
Anavex Life Sciences (AVXL) 的目標價格是多少？
The latest price target for Anavex Life Sciences (NASDAQ: AVXL) was reported by HC Wainwright & Co. on November 28, 2023. The analyst firm set a price target for $54.00 expecting AVXL to rise to within 12 months (a possible 750.39% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月28日公佈了Anavex Life Sciences（納斯達克股票代碼：AVXL）的最新目標股價。該分析公司將目標股價定爲54.00美元，預計AVXL將在12個月內上漲至750.39％（可能上漲750.39％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for Anavex Life Sciences (AVXL)?
Anavex Life Sciences (AVXL) 的最新分析師評級是多少？
The latest analyst rating for Anavex Life Sciences (NASDAQ: AVXL) was provided by HC Wainwright & Co., and Anavex Life Sciences reiterated their buy rating.
Anavex Life Sciences（納斯達克股票代碼：AVXL）的最新分析師評級由HC Wainwright & Co. 提供，Anavex Life Sciences 重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Anavex Life Sciences (AVXL)?
Anavex Life Sciences（AVXL）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on November 28, 2023 so you should expect the next rating to be made available sometime around November 28, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Anavex Life Sciences的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Anavex Life Sciences的最新評級是在2023年11月28日發佈的，因此您應該預計下一個評級將在2024年11月28日左右公佈。
Is the Analyst Rating Anavex Life Sciences (AVXL) correct?
分析師對 Anavex Life Sciences (AVXL) 的評級是否正確？
While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a reiterated with a price target of $0.00 to $54.00. The current price Anavex Life Sciences (AVXL) is trading at is $6.35, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Anavex Life Sciences（AVXL）評級得到了重申，目標股價爲0.00美元至54.00美元。Anavex Life Sciences（AVXL）目前的交易價格爲6.35美元，在分析師的預測區間內。